达巴万星作为金黄色葡萄球菌菌血症治疗选择(DOTS):一项2b期、多中心、随机、开放标签临床试验的研究方案
DOTS是一项2b期、多中心、随机、评估者盲法、优效性、阳性对照、平行组试验,计划纳入200例复杂性金黄色葡萄球菌菌血症成人患者,随机1:1接受达巴万星两剂(第1天和第8天)或4-8周标准静脉抗生素治疗,主要比较第70天结局排名意愿(DOOR),以评估达巴万星是否优效于标准治疗。
要点
- DOTS试验计划纳入200例复杂性金黄色葡萄球菌菌血症成人患者。
- 患者随机1:1接受达巴万星两剂或4-8周标准静脉抗生素治疗。
- 主要终点为第70天结局排名意愿(DOOR),比较达巴万星与标准治疗。
核心结论
- DOTS试验将确立达巴万星在完成复杂性金黄色葡萄球菌菌血症治疗方面是否优效于标准肠外抗生素治疗。
研究设计与样本
- DOTS是一项2b期、多中心、随机、评估者盲法、优效性、阳性对照、平行组试验,计划纳入200例成人复杂性金黄色葡萄球菌菌血症患者。
主要发现
- 主要目标为比较随机分配至达巴万星组与标准治疗组的患者第70天结局排名意愿(DOOR)。
- 关键次要终点包括生活质量结局和达巴万星的药代动力学分析。
关键数值与推荐
- 纳入患者为诊断为复杂性金黄色葡萄球菌菌血症(包括明确或可能的右侧感染性心内膜炎)的成人,已接受有效抗生素治疗至少72小时(最长10天)且随机化前菌血症已清除。
- 受试者随机1:1接受达巴万星两剂(第1天和第8天)或总共4-8周标准静脉抗生素治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staphylococcus aureus bacteremia is a life-threatening infection and leading cause of infective endocarditis, with mortality rates of 15-50%. Treatment typically requires prolonged administration of parenteral therapy, itself associated with high costs and potential catheter-associated complications. Dalbavancin is a lipoglycopeptide with potent activity against Staphylococcus and a long half-life, making it an appealing potential therapy for S. aureus bacteremia without the need for durable central venous access. METHODS: DOTS is a phase 2b, multicenter, randomized, assessor-blinded, superiority, active-controlled, parallel-group trial. The trial will enroll 200 adults diagnosed with complicated S. aureus bacteremia, including definite or possible right-sided infective endocarditis, who have been treated with effective antibiotic therapy for at least 72 h (maximum 10 days) and with subsequent clearance of bacteremia prior to randomization to study treatment. Subjects will be randomized 1:1 to complete their antibiotic treatment course with either two doses of dalbavancin on days 1 and 8, or with a total of 4-8 weeks of standard intravenous antibiotic therapy. The primary objective is to compare the Desirability of Outcome Ranking (DOOR) at day 70 for patients randomized to dalbavancin versus standard of care. Key secondary endpoints include quality of life outcomes and pharmacokinetic analyses of dalbavancin. DISCUSSION: The DOTS trial will establish whether dalbavancin is superior to standard parenteral antibiotic therapy for the completion of treatment of complicated S. aureus bacteremia. TRIAL REGISTRATION: US National Institutes of Health ClinicalTrials.gov NCT04775953 . Registered on 1 March 2021.
引用
- Turner NA, Zaharoff S, King H, et al. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials. 2022. PMID: 35578360. doi:10.1186/s13063-022-06370-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。